Recent events
Recent events tied to this brand in public sources.
Back to profile4 entries
2021
Mirati Therapeutics announces pricing of public stock offering
Mirati Therapeutics announced pricing for an underwritten public offering of 3,448,275 common shares at $145 per share, with gross proceeds expected to be approximately $500 million before expenses. The offering was expected to close on or about November 15, subject to customary closing conditions.
2021
Mirati appoints David Meek as CEO
Mirati Therapeutics appointed David Meek as chief executive officer, effective immediately; he will also join the company's board. Charles M. Baum will continue as president, founder, and head of research and development.
2021
QIAGEN and Mirati collaborate on KRAS companion diagnostic
QIAGEN announced a global collaboration with Mirati Therapeutics to continue developing a tissue-based KRAS companion diagnostic, initially focused on non-small cell lung cancer.
2020
Mirati Therapeutics prices public stock offering
Mirati Therapeutics announced the pricing of an underwritten public offering of 3,076,924 common shares at $97.50 per share; the offering was expected to close on or about January 14, 2020, subject to customary closing conditions.